Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Nocardial pulmonary infection].
Couraud S, Houot R, Coudurier M, Ravel AC, Coiffier B, Souquet PJ. Couraud S, et al. Among authors: houot r. Rev Mal Respir. 2007 Mar;24(3 Pt 1):353-7. doi: 10.1016/s0761-8425(07)91069-4. Rev Mal Respir. 2007. PMID: 17417175 French.
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, Morschhauser F, Navarro R, Le Gouill S, Haioun C, Houot R, Casasnovas O, Holte H, Lamy T, Broussais F, Payrard S, Hatteville L, Tilly H. Coiffier B, et al. Among authors: houot r. Br J Haematol. 2016 Jun;173(5):722-30. doi: 10.1111/bjh.13992. Epub 2016 Mar 24. Br J Haematol. 2016. PMID: 27010483 Free article. Clinical Trial.
A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Ribrag V, Dupuis J, Tilly H, Morschhauser F, Laine F, Houot R, Haioun C, Copie C, Varga A, Lambert J, Hatteville L, Ziti-Ljajic S, Caron A, Payrard S, Coiffier B. Ribrag V, et al. Among authors: houot r. Clin Cancer Res. 2014 Jan 1;20(1):213-20. doi: 10.1158/1078-0432.CCR-13-0580. Epub 2013 Oct 16. Clin Cancer Res. 2014. PMID: 24132920 Clinical Trial.
Cutaneous macroglobulinosis treated with bortezomib and rituximab.
Marchand T, Tas P, Houot R, Dauriac C, Lamy T, Cahu X. Marchand T, et al. Among authors: houot r. Eur J Haematol. 2011 Jul;87(1):98. doi: 10.1111/j.1600-0609.2011.01610.x. Epub 2011 May 25. Eur J Haematol. 2011. PMID: 21418108 No abstract available.
[Malignant lymphoma].
Houot R, Lamy T. Houot R, et al. Rev Prat. 2012 Apr;62(4):547-54. Rev Prat. 2012. PMID: 22641904 Review. French. No abstract available.
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T. Damaj G, et al. Among authors: houot r. J Clin Oncol. 2013 Jan 1;31(1):104-10. doi: 10.1200/JCO.2012.43.7285. Epub 2012 Oct 29. J Clin Oncol. 2013. PMID: 23109692 Clinical Trial.
232 results